BNET Industries
Last Fiscal Year Sales:$1.7M
- Private
- US
Dow Jones Description
Large Scale Biology Corporation's (LSBC) goal is to develop, manufacture and commercialize plant-made pharmaceutical proteins and vaccines. LSBC has successfully garnered an international reputation as an innovator in biomanufacturing. Driven by its unique GENEWARE RNA plant viral gene expression technology, LSBC has taken integration of plant-made pharmaceuticals from gene to production further than any other company. GENEWARE technology is complemented by a full commercial-scale capability to produce, extract, purify, finish and fill a wide range of pharmaceutical proteins. LSBC's proprietary core technologies radically extend the power of product development, improvement and manufacture. LSBC is pursuing an aggressive, market-oriented business model designed to take full advantage of its technological lead and its ability to integrate all major components in the product pipeline. LSBC's technologies and discoveries are protected by an extensive portfolio of foreign and domestic patents, and the company has formed several major alliances and partnerships to maximize its market opportunities. LSBC's ability to bring innovative tools to the forefront of the life sciences industry is well documented, and the company can proudly claim a number of industry firsts, including: the first practical plant-virus-based manufacturing platform, the first release of a safe, transgenic virus into a controlled outdoor environment under government permit, the world's first cancer vaccine...
Vice President and Executive Program Manager
Greg PogueNumber of Employees 20
Contact Information
3333 Vaca Valley Pkwy Ste 1000
Vacaville, California 95688
(707) 446-5501
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Greg Pogue | Vice President and Executive Program Manager |
| Charles Crocker | Director |
| Michael D. Centron | Treasurer |
Gregory Pogue serves as Vice President of Business Development for Emergent Technologies,Inc., and currently serves on the management teams for ETI portfolio companies Pure Vaccine Solutions and Pure Protein as President and Executive Vice President, respectively. As Vice President of Business Development at Emergent Technologies, Dr. Pogue is responsible for evaluating the commercial potential of new technologies, determining both technical and market trajectories, and building partnerships to effectively commercialize products. Dr. Pogue brings over twenty years of experience in biologic development, spanning research management, biologic regulation, and intellectual property development and licensing. Dr. Pogue most recently served as Licensing Associate for the University of Texas at Austin where he negotiated licenses with companies ranging from newly formed startups to Fortune 500 enterprises. Before coming to Texas, Dr. Pogue served as Vice President of Research and Development at Large Scale Biology Corporation (LSBC), where he managed a broad development program involving product development and preclinical and clinical testing of numerous lead compounds, including two receiving Orphan Drug Designation from the US FDA and 16 successfully completing early clinical trials. He also developed licensing and R&D contracts with corporate, academic, and government entities and supervised collaborative research relationships. Before joining LSBC, Dr. Pogue worked in the U.S. FDA's Center for Biologics Research and Evaluation as a scientist with Investigational New Drug and Biological Licensing Application review responsibilities. He holds a B.S. from Midwestern State University and a Ph.D. from Texas A&M University. Pogue has published numerous original scientific articles and reviews, is an inventor on multiple U.S. patents, and is a frequent invited speaker at national and international scientific meetings.
| Organization | Position | Status |
|---|---|---|
| Pure Protein, Inc. | President, Pure Vaccine Solutions, Executive Vice President | Current |
| Large Scale Biology Corporation | Vice President and Executive Program Manager | Current |
| Emergent Technologies, Inc. | Vice President of Business Development | Current |
| The University of Texas at Austin | Licensing Associate | Former |
| Lsbc Ltd | Former | |
| Texas A&M University | Ph.D. | Former |
| Midwestern State University | B.S. | Former |
| Organization | Position | Status |
|---|---|---|
| Genelux Corporation | Chairman and CEO, Crocker Capital, California | Current |
| Crocker Capital, Inc. | CEO | Current |
| Genelux Corporation | Business Advisor | Current |
| S.O.S. Newall Limited | Current | |
| Crocker Capital, Inc. | Chairman of the Board | Current |
| Pope & Talbot, Inc. | Chairman of Board | Current |
| The Mary A. Crocker Trust | Board of Directors | Current |
| Storm Products Company Corp | Board of Directors | Current |
| Vicus Therapeutics, LLC | Director | Current |
| Mercator Medsystems, Inc | Board of Directors | Current |
| Large Scale Biology Corporation | Director | Current |
| Superconductor Technologies, Inc. | Director | Current |
| Teledyne Technologies Incorporated | Director | Current |
| Fiduciary Trust Company International | Director | Current |
| Coopervision, Inc. | Director | Current |
| The Mary A. Crocker Trust | Trustee | Current |
| Teledyne Technologies Incorporated | Member of the Personnel & Compensation Committee | Current |
| Bei Medical Systems Co., Inc. | CEO | Former |
| BEI Technologies, Inc. | CEO | Former |
| Bei Medical Systems Co., Inc. | Founder | Former |
| Schneider Electric | Founder | Former |
| Crocker Capital, Inc. | Principal | Current |
| Children's Hospital | Chairman of the Board | Former |
| BEI Technologies, Inc. | Chairman of the Board | Former |
| Pope & Talbot, Inc. | Director | Former |
| University of California, Berkeley | M.B.A | Former |
| Stanford University | B.S. Degree | Former |
Michael D. Centron, Vice President and Treasurer, joined the Company in 1988 and has served as Treasurer since 1991. Prior to joining LSBC, Mr. Centron was Audit Supervisor for Varian Associates from 1985-1988, and also worked for Arthur Young and Co. (currently Ernst & Young). Mr. Centron is a certified public accountant and received his M.B.A. degree from the University of California, Berkeley.
| Organization | Position | Status |
|---|---|---|
| Large Scale Biology Corporation | Treasurer | Current |
| Varian Semiconductor Equipment Associates, Inc. | Audit Supervisor | Former |
| Arthur Young, Inc. | Former | |
| University of California, Berkeley | M.B.A. Degree | Former |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes

